CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Hwail Pharm Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Hwail Pharm Co Ltd
57, Jeyakgongdan 3-gil, Hyangnam-eup
Phone: +82 313534101p:+82 313534101 HWASEONG, 18622  South Korea Ticker: 061250061250
Business Summary
Hwail Pharm Co Ltd is a Korea-based company mainly engaged in the manufacture and distribution of pharmaceutical raw materials. The Company mainly produces aceclofenac, lornoxicam, triflusal, dicloalphenazone, gallamine triethyl iodide, acemetacin, levosulpiride, alibendol, erdostein, talniflumate, topiramate, phloroglucin, oxatomide and others used as expectorants, cough remedies, antispasmodics, analgesics, anti-inflammatories and others under the brand name EDST, TRPR, LVSP, ACCL and others. The Company also provides finished formulations, including injection products such as ceftazidime, cefoperazone, cefotaxime, cefaclor, cefatrizine, cefroxadine and others.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202512/31/2024Yes----

Industries
SIC Code Description
2833 Medicinal chemicals and botanical products
6512 Operators of nonresidential buildings

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chief Executive Officer, Director Gyeong SukCho 64 3/24/2023 9/18/2020
Co-Chief Executive Officer, Director Saeng GyuSeo 64 2/1/2023 2/1/2023
Vice President, Director Yeong CheolJung 57 1/1/2011 1/1/2007
8 additional Officers and Directors records available in full report.

Business Names
Business Name
061250
Hwail Pharma Co., Ltd.

General Information
Number of Employees: 161 (As of 6/30/2025)
Outstanding Shares: 84,175,847 (As of 7/31/2025)
Shareholders: 20,916
Stock Exchange: KDQ
Fax Number: +82 25614897


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, September 6, 2025
Register now for our FAST Rating webinar on September 10 at 2:00 PM ET!